| Heading: |
Prescription Drugs |
| Question ID: |
1787402 |
| UIN: |
40416 |
| House: |
Commons |
| Date tabled: |
2025-03-21 |
| Asking Member ID: |
5340 |
| Asking Member display name: |
Jack Rankin
|
| Asking Member handle: |
jackmrankin
|
| Asking Member Twitter reference: |
@jackmrankin
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to SGLT2 inhibitors for patients with (a) type 2 diabetes, (b) chronic kidney disease and (c) heart failure. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-03-27 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based best practice guidance for the National Health Service.The NICE has been able to recommend two SGLT2 inhibitors, ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |